Mark Cuban: Health Insurance Companies are Playing a 'Tax Arbitrage' Game
Investor Mark Cuban pointed out that most Medicare Advantage, Medicare Part D, and managed Medicaid insurers do not truly rely on government health insurance itself, but rather on their ability to arbitrage "taxpayer capital." He explained that insurance companies first receive capitation payments, then outsource the actual delivery of medical services to their own or value-based care (VBC) companies, which bear the cost risk and charge lower prices, with the difference becoming the insurer's profit.
He further stated that insurers have also outsourced processes like "treatment denial" and "peer-to-peer review" to third-party service providers controlled by private equity (PE), which are not accountable to patients and often do not disclose their identities, thereby shifting all responsibility and accountability for "blocking treatment and denying payment" away.
Research on U.S. healthcare policy and regulation also shows that some managed care insurers in Medicare Advantage and Medicaid Managed Care have stripped significant medical costs and policy risks from their balance sheets through subcontracting, risk layering, and reinsurance arrangements, repackaging them into a structure of "management fees + reallocation," thereby nominally "controlling costs" while actually "harvesting price differences."
Source: Public Information
ABAB AI Insight
This structure essentially turns the "health insurance payment chain" into multiple arbitrage opportunities through layers of intermediaries. The government hands over the budget to insurers in the form of capitation, who then package actual medical services to lower-risk, more flexible VBC and PE entities, while outsourcing disputes and accountability to another set of PE-controlled denial companies. This macro-level structure transforms payments into "government as the source, insurers as the middlemen, and PE profiting at both ends," while the real risk and reputational costs are often borne by patients, doctors, and community hospitals.
In terms of incentives, this outsourcing merges "cost control" and "risk control" into a single goal, rather than differentiating between "cost control" and "quality assurance." When insurers push "hard-to-manage" patients and high-risk groups to external entities and delegate "denials and reviews" to PE service providers, the system naturally encourages "killing with rules rather than treating with medicine." Under this abstract logic, metrics like payout rates, denial rates, risk scores, and renegotiation costs become more "quantifiable" and "optimizable" than actual cure rates and survival times.
From a long-term structural perspective, this also explains why the U.S. healthcare system, while "spending more money," has not seen a corresponding improvement in quality and accessibility. A significant amount of capital profits through "healthcare tiered arbitrage" rather than "productivity enhancement," converting public budgets into a series of tradable intermediary profit pools. To truly change this situation, regulation must not only focus on "premiums and reimbursement rates" but also penetrate into the gray areas of "subcontracting, PE-controlled service providers, and denial chains" to clearly expose the structure of "who is at risk and who is outside of responsibility."